

Corporate Fact Sheet

EMERGENT BIOSOLUTIONS

We are a global life sciences company seeking to **protect and enhance life** by focusing on providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. Through our work, we envision protecting and enhancing 50 million lives with our products by 2025.

OPERATIONS

Headquarters: Gaithersburg, MD

Manufacturing Facilities: United States, Canada

Product Development Sites: United States, Canada

Services: Contract manufacturing

Product Portfolio: Vaccines and therapeutics focused on biological threats/emerging infectious diseases, as well as devices for chemical threats

PORTFOLIO AS OF OCTOBER 2017

PRODUCT / PRODUCT CANDIDATE	TARGET	TYPE	PLATFORM/TECHNOLOGY	STAGE
BioThrax® Anthrax Vaccine Adsorbed	Anthrax Biological Threat	Vaccine	—	Marketed ■ ■ ■ ■ ■
Raxibacumab Anthrax Monoclonal Antibody	Anthrax Biological Threat	Therapeutic	—	Marketed ■ ■ ■ ■ ■
RSDL® Reactive Skin Decontamination Lotion Kit	Chemical Agents Chemical Threat	Device	—	Marketed ■ ■ ■ ■ ■
BAT® Botulism Antitoxin Heptavalent (A,B,C,D,E,F,G)-(Equine)	Botulism Biological Threat	Therapeutic	Hyperimmune	Marketed ■ ■ ■ ■ ■
VIGIV Vaccinia Immune Globulin Intravenous (Human)	Smallpox¹ Biological Threat	Therapeutic	Hyperimmune	Marketed ■ ■ ■ ■ ■
Anthrasil® Anthrax Immune Globulin Intravenous (Human)	Anthrax Biological Threat	Therapeutic	Hyperimmune	Marketed ■ ■ ■ ■ ■
Trobigard™ atropine sulfate, obidoxime chloride	Nerve Agent Chemical Threat	Drug/Device	Auto-injector	Ex-US Sales ² ■ ■ ■ ■ ■
NuThrax™ anthrax vaccine adsorbed with CPG 7909 adjuvant	Anthrax Biological Threat	Vaccine	—	Phase 3 ^{3,4} ■ ■ ■ ■ ■
FLU-IGIV	Seasonal Influenza Emerging Infectious Disease	Therapeutic	Hyperimmune	Phase 2 ⁵ ■ ■ ■ ■ ■
UV-4B	Dengue Emerging Infectious Disease	Therapeutic	Antiviral	Phase 1 ■ ■ ■ ■ ■
ZIKV-IG	Zika Emerging Infectious Disease	Therapeutic	Hyperimmune	Phase 1 ⁵ ■ ■ ■ ■ ■
GC-072	Burkholderia Emerging Infectious Disease	Therapeutic	Antibacterial	Pre-clinical ■ ■ ■ ■ ■
FILOV	Pan filovirus (Ebola, Marburg, Sudan) Emerging Infectious Disease	Therapeutic	Hyperimmune, Monoclonal Ab	Pre-clinical ■ ■ ■ ■ ■

¹ Indicated for adverse events associated with the Smallpox vaccine

² Not approved by US FDA or other regulatory agencies; only sold outside of the United States to authorized government buyers

³ Status reflects both clinical and nonclinical development under the FDA Animal Rule

⁴ First subject enrollment targeted for 2018

⁵ First subject enrollment targeted for 2017

PLATFORMS & TECHNOLOGIES



Hyperimmunes

Human and equine plasma products generated for targeted therapy of specific indications

Human Platform

Purified gamma globulin (IgG) containing polyclonal antibodies to specific antigen(s) obtained from human plasma


Equine Platform

Purified immune globulin fragments derived from polyclonal antibodies to specific antigen(s) obtained from equine plasma



Auto-injector

The Emergard® auto-injector platform is designed for intramuscular rapid delivery of nerve agent antidotes and other emergency response medical treatments



Antivirals

Broad-spectrum antiviral iminosugars that inhibit a host glycosylation pathway resulting in misfolded viral glycoproteins, subsequently leading to reduced viral infectivity



Antibacterials

EV-035 series of broad spectrum antibiotics have a novel 4-oxoquinolizine antibacterial backbone showing activity against quinolone-resistant bacterial strains



MVAator™

(Modified vaccinia virus Ankara vector)
MVAator is a flexible, proprietary, viral vector platform for delivery of protective or therapeutic antigens

RECENT BUSINESS HIGHLIGHTS

- ▶ Announced closing of new \$200 Million Senior Secured Credit Facility
- ▶ Contract valued at up to \$171 Million to supply DoD with RSDL
- ▶ BARDA contract valued at up to \$63 Million to develop treatment for cyanide exposure
- ▶ Awarded \$23 Million to develop novel multi-drug auto-injector for U.S. Department of Defense
- ▶ Worldwide rights to Valneva's Zika vaccine technology secured
- ▶ Acquisition of ACAM2000 business from Sanofi announced
- ▶ Contract Modification Valued at up to \$53 Million Received from BARDA for the Manufacture of Botulism Antitoxin
- ▶ Contracts Valued at up to \$1 Billion Awarded by HHS for BioThrax Deliveries to the Strategic National Stockpile
- ▶ Task Order Valued at Up to \$30.5 Million Received from BARDA to Develop Viral Hemorrhagic Fever Therapeutics
- ▶ Contract Valued at Up to \$1.6 Billion Awarded by BARDA for Advanced Development and Delivery of NuThrax

FINANCIAL HIGHLIGHTS

	Total Revenue (dollars in millions)	Net Income (dollars in millions)	Cash (dollars in millions)	EBITDA (dollars in millions)
2016	489	63	272	142
2015	489	91	308	173
2014	404	54	277	123
2013	313	71	179	102
2012	278	58	142	78

Our historical results for any prior period are not necessarily indicative of results to be expected in any future period.

CONTACT INFORMATION

Corporate
400 Professional Drive, Suite 400
Gaithersburg, MD 20879 USA
Tel: 240-631-3200 Fax: 240-631-3203

Investor Relations: Robert Burrows, burrowsr@ebsi.com
Media: Lynn Kieffer, kiefferl@ebsi.com
Business Development: BD@ebsi.com
emergentbiosolutions.com

